NeuroPace, Inc. $NPCE Shares Purchased by Walleye Capital LLC

Key Points

• Walleye Capital LLC increased its stake in NeuroPace, Inc. by 311.7% during the first quarter, bringing its total shares owned to 117,536, valued at approximately $1.45 million.
• NeuroPace reported a quarterly loss of ($0.26) EPS, missing projections, but did achieve revenues of $23.52 million, slightly above estimates.
• Investment analysts maintain a consensus rating of "Moderate Buy" for NeuroPace, with an average target price of $16.60, despite recent fluctuations in target estimates from various firms.

Walleye Capital LLC grew its position in NeuroPace, Inc. (NASDAQ:NPCE - Free Report) by 311.7% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 117,536 shares of the company's stock after buying an additional 88,989 shares during the period. Walleye Capital LLC owned 0.36% of NeuroPace worth $1,445,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Rhumbline Advisers raised its position in shares of NeuroPace by 15.2% in the 1st quarter. Rhumbline Advisers now owns 17,227 shares of the company's stock valued at $212,000 after purchasing an additional 2,267 shares during the last quarter. Wells Fargo & Company MN raised its position in shares of NeuroPace by 54.2% in the 4th quarter. Wells Fargo & Company MN now owns 6,483 shares of the company's stock valued at $73,000 after purchasing an additional 2,279 shares during the last quarter. BNP Paribas Financial Markets purchased a new position in shares of NeuroPace in the 4th quarter valued at approximately $29,000. Charles Schwab Investment Management Inc. raised its position in shares of NeuroPace by 7.4% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 39,237 shares of the company's stock valued at $482,000 after purchasing an additional 2,700 shares during the last quarter. Finally, GAMMA Investing LLC purchased a new position in shares of NeuroPace in the 1st quarter valued at approximately $53,000. 78.83% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently commented on NPCE shares. HC Wainwright started coverage on shares of NeuroPace in a research report on Wednesday, May 28th. They issued a "buy" rating and a $18.00 price objective for the company. Zacks Research lowered shares of NeuroPace from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, August 13th. JPMorgan Chase & Co. raised their price target on shares of NeuroPace from $14.00 to $16.00 and gave the stock an "overweight" rating in a research report on Wednesday, May 14th. Wells Fargo & Company reduced their price target on shares of NeuroPace from $17.00 to $15.00 and set an "overweight" rating for the company in a research report on Wednesday, August 13th. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $17.00 price target on shares of NeuroPace in a research report on Wednesday, May 14th. Five investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $16.60.

NeuroPace Stock Performance

Shares of NASDAQ:NPCE traded up $0.13 during trading on Wednesday, hitting $9.27. 151,584 shares of the stock traded hands, compared to its average volume of 270,665. The company has a quick ratio of 4.51, a current ratio of 5.47 and a debt-to-equity ratio of 3.02. The company has a market cap of $306.65 million, a price-to-earnings ratio of -11.05 and a beta of 1.90. The company has a fifty day moving average price of $9.33 and a two-hundred day moving average price of $11.36. NeuroPace, Inc. has a 52-week low of $5.45 and a 52-week high of $18.98.

NeuroPace (NASDAQ:NPCE - Get Free Report) last posted its earnings results on Tuesday, August 12th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.02). The firm had revenue of $23.52 million for the quarter, compared to analysts' expectations of $23.08 million. NeuroPace had a negative net margin of 29.29% and a negative return on equity of 168.61%. NeuroPace has set its FY 2025 guidance at EPS. As a group, equities analysts predict that NeuroPace, Inc. will post -1 EPS for the current year.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.